Video
9 Nov 2022

The German Pharmaceutical Market - Post-Pandemic Recovery and Key Trends

CPHI is back in Frankfurt, an important hub for the German pharmaceutical community. This session will explore the German market and look at the abundance of innovation emerging from one of Europe's biggest pharma hubs.
This session will touch upon:

  • Access to Innovative Medicines and Launch Performance
  • Developments in Generics and Biosimilars
  • Initiatives Towards Further Digitalization
Did you enjoy this session? If so, you might like to visit our Connect to Frankfurt platform, where you can browse our collection of 30+ on-demand webinars and learn about our upcoming CPHI Frankfurt event, taking place 1-3 November in Frankfurt, Germany.
Bringing together the global supply chain under one roof, CPHI Frankfurt puts you at the heart of pharma. Can’t attend in person? You can access many of the event offerings online! Browse our exhibitor list, arrange meetings, view on-site content and network – all from home.

Click here to register

Content provided by our supplier

IQVIA

  • GB
  • 2015
    On CPHI since
  • 5000+
    Employees
Company types
Consultancy

Other Content from IQVIA (4)

  • News CPHI releases Pharma Trends 2022 report

    CPHI has launched its forward-looking pharma trend report for 2022 and it is now available to read on CPHI Online.
  • Webinar Trends in Drug Delivery

    In this webinar, originally broadcast as part of the Pharmapack Europe show, speaker Aurelio Areas, Engagement Manager, IQVIA will give us a look at the global outlook of the pharma industry as it emerges from the pandemic with a focus on drug delivery trends. This session analyses current dynamics in drug delivery devices and look at emerging growth areas such as the rise of self-administration, connectivity and the impact of devices on our environment.
  • Webinar Developments in the Cold-Chain

    In this webinar, originally broadcast as part of the Pharmapack Europe show, Stefan Lutzmayer, Consultant, IQVIA discusses how as biologics and specialty medicines increase in importance in global healthcare, especially when access to medicines and biosimilars become growth areas, this brings various opportunities in developing the logistical network that delivers these medicines to patients in a temperature-controlled environment. This session explores the rapid growth of cold-chain medicines and seek to understand their impact on health provision and the environment.
  • Webinar Why the Pharma Industry Must Address their Carbon Footprint

    Rapid climate change has direct impacts on human health. These arise from multiple causes, including severe weather, changing ecology of disease vectors, increased allergens, and geopolitical conflict over scarce resources.
    Healthcare itself contributes to climate change because of its sizeable carbon footprint. It follows that health systems should be frontrunners in reducing its carbon footprint to limit the impact of climate change and mitigate poorer health outcomes and inequity.
    Many health systems have identified medicines as one of the largest single contributors to their carbon footprint. This session will evaluate the pharma industry’s carbon footprint and provide recommendations on what we can do to reduce emissions, meet environmental targets, and consequently open a new path to supporting human health.